Life Science

Top 3 legal predictions on Life Sciences for 2020

By Marco de Morpurgo, Nicola Landolfi and Chiara Perotti Last year was a pivotal year for the Life Sciences industry. As we had foreseen, 2019 witnessed significant technological and regulatory progress. Digitalization of the medical sector has impacted the way pharmaceutical and medical device companies approach patients, with smoother communication means that bring to zero the physical distance between patients, healthcare professionals, and the industry. In parallel, cell and gene therapies – which require sophisticated and precision development techniques – are shaking the market, increasingly establishing themselves as the “medicine of the future”. In this continuously evolving environment, Life Sciences …

Top 3 legal predictions on Life Sciences for 2020 Read More »

Top 3 Legal Predictions on Electronic Cigarettes and Novel Tobacco Products for 2020

By Francesca Romana Ferrucci and Alessandro Ferrari 2019 was a very interesting year for tobacco, electronic cigarettes (“e-cigs”) and novel tobacco products (“NTPs”) all around the world. Going from new products in the process of accessing new markets, moving on with the mayhem concerning severe health issues allegedly connected to the use of e-cigs. The past year has definitely been quite a rollercoaster for the sector and the upcoming year is likely to be just as intense. Marketing and advertisement: the saga continues As highlighted in our previous legal predictions for 2019, the Italian legal background concerning marketing and advertisement …

Top 3 Legal Predictions on Electronic Cigarettes and Novel Tobacco Products for 2020 Read More »

Top 3 predictions for life sciences in 2019

The Life Sciences industry operates in one of the fastest and most innovation-driven environments. 2018 has witnessed significant developments in technology and therapeutic practices. A number of new cell and gene therapies – including the first two CAR-T therapies for cancer – received EU approval, and both disruptive and ‘new mainstream’ technologies (such as AI) made significant steps forward into the sector.

The pharmaceutical and medical device sectors are also among the most heavily regulated. Life Sciences companies face significant challenges in managing regulatory compliance in an environment where regulation constantly evolves. Moreover, the sector moves so fast that it is hard for regulation to keep up with the pace of technological development.

Read more »